M. Porcheron

Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection

J. Izopet, G. Martin-Blondel, C. Dimeglio, 2022, Vaccines.

One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection

J. Izopet, G. Martin-Blondel, C. Dimeglio, 2021, Journal of Infection.

Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant

J. Izopet, C. Dimeglio, F. Hérin, 2022, Microbiology spectrum.

Current immunoassays and detection of antibodies elicited by Omicron SARS‐CoV‐2 infection

C. Dimeglio, M. Miédougé, M. Pucelle, 2022, Journal of medical virology.

Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

J. Fillaux, J. Izopet, F. Abravanel, 2021, Microbiology spectrum.

Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status

I. Pommepuy, A. Chaunavel, F. Labrousse, 2011, Journal of Clinical Pathology.

Modelling and expression of the extracellular domain of the human guanylyl cyclase C receptor

M. Porcheron, 2011 .

Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response

J. Izopet, G. Martin-Blondel, C. Dimeglio, 2022, Journal of Infection.

Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2

J. Izopet, G. Martin-Blondel, C. Dimeglio, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population

J. Izopet, H. Villars, C. Dimeglio, 2023, Vaccines.